ArticleNeurospine2024
Comparative Review of the Socioeconomic Burden of Lower Back Pain in the United States and Globally.
Article in Neurospine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Assistive technologies (lumbar supports and other devices) for treating chronic low back pain.The Cochrane database of systematic reviews · 2026Pooled it
- Deep learning for the diagnosis of lumbar disc herniation: a systematic review and meta-analysis.BMC medical imaging · 2026Pooled it
- Trial
- Effects of auricular point acupressure on inflammatory signaling in chronic low back pain: a secondary analysis of a randomized controlled trial.BMC complementary medicine and therapies · 2025Trial
- Baseline characteristics of participants in the Biomarkers for Evaluating Spine Treatments clinical trial: a sequential multiple assignment randomized trial for chronic low back pain†.Pain medicine (Malden, Mass.) · 2025Trial
- Durable Outcomes and Intervention Avoidance in Low Back Pain Up to 5 Years After Percutaneous 60-Day Peripheral Nerve Stimulation.Pain and therapy · 2026Article
- UCHL3 drives ferroptosis in nucleus pulposus cells by deubiquitinating HMGB1 to activate NCOA4-mediated ferritinophagy.Autophagy · 2026Article
- Artificial Intelligence for Clinical Decision Support in Rural Spine Care: A Narrative Review.Healthcare (Basel, Switzerland) · 2026Review
- Brain dysconnectivity patterns associated with chronic back pain development.Brain informatics · 2026Article
- Article
- Long-term Pain and Function Outcomes Associated With Lumbar Spine Surgery for Chronic Low Back Pain: A Target Trial Emulation.International journal of spine surgery · 2026Article
- Trends in the burden of low back pain attributable to occupational ergonomic factors among the global population aged 15-64 years (1990-2021): a study based on the GBD database.Journal of health, population, and nutrition · 2026Article
- Preconditioning Mesenchymal Stem Cells to Enhance Performance in the Degenerate Nucleus Pulposus.Tissue engineering. Part B, Reviews · 2026Review
- Combined Double-Coil and Handheld rPMS in Low Back Pain: An Observational Case Series Based on Routine Clinical Practice.Life (Basel, Switzerland) · 2026Article
- Article
- Foraminal [AJNR. American journal of neuroradiology · 2026Observational
- Mendelian randomization analysis identifies HLA-A and AP2M1 as genetic biomarkers linked to immune-endocytic crosstalk in intervertebral disc degeneration.Journal of cell communication and signaling · 2026Article
- Analysis of National Institutes of Health funding for back pain research in the United States.North American Spine Society journal · 2026Article
- Intervertebral disc degeneration.Nature reviews. Disease primers · 2026Review
- Impact of Menopause and Associated Hormonal Changes on Spine Health in Older Females: A Review.Cells · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Internationally, the United States (U.S.) cites the highest cost burden of low back pain (LBP). The cost continues to rise, faster than the rate of inflation and overall growth of health expenditures. We performed a comprehensive literature review of peer-reviewed and non- peer-reviewed literature from PubMed, Scopus, and Google Scholar for contemporary data on prevalence, cost, and projected future costs. Policymakers in the U.S. have long attempted to address the high-cost burden of LBP through limiting low-value services and early imaging. Despite these efforts, costs (~$40 billion; ~$2,000/patient/yr) continue to rise with increasing rates of unindicated imaging, high rates of surgery, and subsequent revision surgery without proper trial of non-pharmacologic measures and no corresponding reduction in LBP prevalence. Globally, the overall prevalence of LBP continues to rise largely secondary to a growing aging population. Cost containment methods should focus on careful and comprehensive clinical assessment of patients to better understand when more resource-intensive interventions are indicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.